Healthcare Providers Weigh In on Adjunctive Digital Schizophrenia Therapy

Psychiatrists and psychologists were surveyed about their expectations for an adjunctive digital therapeutic created to treat schizophrenia.

The following article is a part of conference coverage from Psych Congress 2021 , held October 29th through November 1, 2021, in San Antonio, Texas. The team at Psychiatry Advisor will be reporting on the latest news and research conducted by leading experts in psychiatry. Check back for more from the Psych Congress 2021.


Mental health providers have responded to a survey regarding their expectations for an adjunctive digital therapeutic treatment for schizophrenia, according to study results recently presented at Psych Congress 2021, held from October 29 to November 1, 2021, in San Antonio, Texas.

This study presents data collected from a survey sent to 33 psychiatrists and 18 psychologists who were asked to share their expectations for an adjunctive digital therapeutic created to treat schizophrenia. These 51 healthcare providers spend up to 25% of their time treating individuals with schizophrenia in an outpatient setting. The survey consisted of 10 questions, and healthcare providers were asked to rank responses to elucidate their personal preferences for the digital therapeutic.

Survey respondents indicated that the greatest challenges endured by those with schizophrenia included adhering to medication (31%), impaired functioning (22%), and impaired cognition (10%). In terms of current schizophrenia treatment, the providers ranked the population’s greatest unmet needs as better functioning (24%), better adherence to medication (16%), reducing relapse (12%), and improving social support (12%). The providers reported their expectations for what the digital therapeutic might include. Their top options included reminders for medication (37%), integration for social support (14%), and cognitive restructuring (12%).

The study authors concluded that “healthcare providers see the potential for digital therapeutics to act as an adjunct to standard-of-care pharmacotherapy to address several of the known limitations in the treatment of schizophrenia.”

Disclosure: This clinical trial was supported by Click Therapeutics and Boehringer Ingelheim Pharmaceuticals. Please see the original reference for a full list of authors’ disclosures.


Visit Psychiatry Advisor’s meetings section for complete coverage of Psych Congress 2021.



Campellone T, Carretta C, Davidson C, Lakhan S, Sand M. Assessing the unmet clinical need and opportunity for digital therapeutic intervention in schizophrenia: perspective from healthcare providers. Presented at: Psych Congress 2021; October 29-November 1, 2021; San Antonio, TX. Poster 20.